Novo Nordisk and Glooko are teaming-up to jointly develop digital health solutions for people with diabetes. The non-exclusive collaboration will combine Novo Nordisk’s deep knowledge of diabetes with Glooko’s digital platform and data analytics expertise.
Building on Glooko’s mobile and web platforms, the companies aim to deliver personalized, digital services to support people with diabetes in areas such as treatment adherence and blood glucose management. The joint offerings will also provide healthcare professionals with population health management capabilities.
“We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control,” Christian Kanstrup, senior vice president, Strategy, Access & Marketing, Novo Nordisk said in a statement. “Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”
Glooko is a leading population health platform for diabetes management and enables people with diabetes to more easily track and better manage their condition using mobile, web and cloud technology. Also, the solution makes it easier for care teams to remotely support patients, and aims to improve patient satisfaction and outcomes at a lower cost.
“We look forward to delivering jointly-branded capabilities that will enhance the collaboration between patient and healthcare professionals and enable us to provide joint offerings to people living with diabetes around the world,” Rick Altinger, Glooko CEO, said in a statement.